Patents by Inventor Carl H. June

Carl H. June has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11001805
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: May 11, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Patent number: 10981969
    Abstract: The present invention relates generally to a fusion protein that when displayed on a cell can convert a negative signal into a positive signal in the cell. The fusion protein is a chimeric protein in that the protein comprises at least two domains, wherein the first domain is a polypeptide that is associated with a negative signal and the second domain is a polypeptide that is associated with a positive signal. Thus, the invention encompasses switch receptors that are able to switch negative signals to positive signals for enhancement of an immune response.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: April 20, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Yangbing Zhao
  • Publication number: 20210060071
    Abstract: The present invention includes compositions and methods for treating atherosclerosis. In certain embodiments, atherosclerosis is treated using a chimeric antigen receptor (CAR) T cell specific for modified low-density lipoprotein.
    Type: Application
    Filed: April 26, 2019
    Publication date: March 4, 2021
    Inventors: Avery D. POSEY, Carl H. JUNE, Robert D. SCHWAB
  • Patent number: 10927184
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: February 23, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
  • Publication number: 20210047405
    Abstract: The invention provides methods for manufacturing optimized CAR T cell therapies and uses thereof. Specifically, the invention provides parameters that can be measured, e.g., evaluated, to manufacture CAR T cell therapies with optimized properties. The invention further provides methods of use in connection with said optimized CART cells.
    Type: Application
    Filed: April 26, 2019
    Publication date: February 18, 2021
    Inventors: Christopher Loren Nobles, Frederic Dixon Bushman, Joseph A. Fraietta, Simon Lacey, Jan J. Melenhorst, Carl H. June
  • Publication number: 20210038659
    Abstract: The invention provides compositions and methods for treating diseases such as cancer. The invention also relates to a method of administering a chimeric antigen receptor (CAR) therapy and an additional therapeutic agent, e.g., one or more cytokine molecules, e.g., a virus comprising a nucleic acid molecule encoding one or more cytokine molecules.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 11, 2021
    Inventors: Carl H. June, Watanabe Keisuke, Sonia Guedan Carrio, Akseli Hemminki, John Scholler, Regina M. Young
  • Publication number: 20210040234
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.
    Type: Application
    Filed: June 24, 2020
    Publication date: February 11, 2021
    Inventors: Carl H. June, Yangbing Zhao, Xiaojun Liu
  • Publication number: 20210009652
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
    Type: Application
    Filed: February 17, 2020
    Publication date: January 14, 2021
    Inventors: Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
  • Publication number: 20210008188
    Abstract: The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 14, 2021
    Inventors: Yangbing Zhao, Carl H. June, Xiaojun Liu
  • Publication number: 20200407728
    Abstract: The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR ? chain, TCR ? chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
    Type: Application
    Filed: July 30, 2020
    Publication date: December 31, 2020
    Inventors: Yangbing Zhao, Jiangtao Ren, Xiaojun Liu, Carl H. June
  • Publication number: 20200407460
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Application
    Filed: January 23, 2020
    Publication date: December 31, 2020
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Patent number: 10874727
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: December 29, 2020
    Assignees: The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Publication number: 20200399383
    Abstract: The invention provides compositions and methods for treating diseases such as cancer. The invention also relates to a method of administering a therapy comprising a chimeric antigen receptor, an IL-15R molecule and an IL-15 molecule.
    Type: Application
    Filed: February 13, 2019
    Publication date: December 24, 2020
    Inventors: John Scholler, Carl H. June
  • Publication number: 20200377589
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: January 15, 2020
    Publication date: December 3, 2020
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • Publication number: 20200370012
    Abstract: The disclosure provides methods of making CAR-expressing immune effector cells (e.g., T cells, or NK cells), and compositions and reaction mixtures comprising the same. The disclosure further provides methods of using said CAR-expressing immune effector cells.
    Type: Application
    Filed: October 25, 2018
    Publication date: November 26, 2020
    Inventors: Joseph A. Fraietta, Jan J. Melenhorst, Elena Orlando, Roderick O'Connor, Carl H. June
  • Publication number: 20200368268
    Abstract: The invention provides compositions and methods for treating diseases such as cancer. The invention also relates to a method of administering a chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
    Type: Application
    Filed: January 8, 2019
    Publication date: November 26, 2020
    Inventors: Lexus R. Johnson, Carl H. June, Andy J. Minn
  • Publication number: 20200360431
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
    Type: Application
    Filed: November 15, 2018
    Publication date: November 19, 2020
    Inventors: Alfred Garfall, Adam David Cohen, Michael C. Milone, Gabriela Plesa, Edward A. Stadtmauer, Carl H. June
  • Patent number: 10829735
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 10, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Patent number: 10828353
    Abstract: The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 10, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Carl H. June, Xiaojun Liu
  • Publication number: 20200339651
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 29, 2020
    Inventors: Jennifer Brogdon, Gregory Beatty, David Jonathan Glass, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Huijuan Song, Qilong Wu